PROGNOSTIC ROLE OF THE FGFR4-388ARG VARIANT IN LUNG SQUAMOUS CELL CARCINOMA PATIENTS WITH LYMPH NODE INVOLVEMENT

The identification of prognostic biomarkers and novel therapeutic targets in lung squamous cell carcinoma (SCC) is crucial. We analyzed the presence of the FGFR4-388Arg variant in 114 SCC patients and related it to increased MAPK signaling, and to reduced survival in lymph node-affected patients. These findings suggest that FGFR4 targeting in these patients may be a potential therapeutic strategy.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2q4gufo
via IFTTT